Retrospective Study Evaluating Hypofractionated Radiotherapy Concomitantly with Weekly Boost for Early Breast Cancer Patients Treated with Conservative Breast Surgery | ||||
| SECI Oncology Journal | ||||
| Volume 11, Issue 4, October 2023, Page 306-313 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Background: Breast cancer is the most life- threatening cancer, as it remains leading cause of women death among less developed countries, however in developed countries. Based on radiobiological models, it was evident that hypofractionated radiation schedules used as adjuvant treatment for breast cancer offer equivalent local control to standard conventional radiation therapy by giving larger doses per fraction in shorter period of time. Patients & Methods: This retrospective study included 50 female patients with early stage (T1-2 N0-1 M0) breast cancer who underwent breast conservative surgery. All patients received adjuvant radiotherapy at the radiotherapy department of South Egypt Cancer Institute (SECI), Assiut University, Egypt, between 2013 and 2016. All patients received post-operative chemotherapy then adjuvant whole breast radiotherapy (42.5GY/16 fractions) with once weekly concomitant photon boost of 1 GY for 3 weeks (total boost dose 3GY) with whole radiotherapy schedule period of 16 days (3 weeks). The patients were followed up for 60 months. Results: The 5 years disease free survival was 94% and the local recurrence 2%, distant metastasis 4%, and 5 years overall survival was 96%. Cosmetic outcome was Excellent or good in most of cases, with few poor and fair outcomes. Conclusion: hypofractionation with integrated boost as adjuvant treatment for breast cancer is an acceptable option that provides excellent local control and low toxicity. Hypofractionated whole breast irradiation with concomitant weekly boost appears feasible and safe. | ||||
| Keywords | ||||
| Breast cancer; hypofractionation; Toxicity; Concurrent boost | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 37 |
||||
